Domperidone Should NOT Be Used for Feeding Intolerance or Reflux Prevention in Premature Infants
Domperidone is not approved for use in humans in the United States and lacks robust evidence for treating gastroesophageal reflux or feeding intolerance in premature infants. 1
Key Evidence Against Domperidone Use
Regulatory Status
The FDA explicitly states that domperidone is "not approved for any indication in humans in the US" and warns that "pregnant and lactating women should use caution when handling" the veterinary formulation due to potential effects on reproductive hormones 1. This is a critical safety consideration that supersedes any potential theoretical benefits.
Lack of Efficacy Evidence
The most comprehensive systematic review (2023 Cochrane) examining pharmacological treatments for GER in children found insufficient summary data to assess domperidone and concluded there is only "very low-certainty evidence" for any medication improving outcomes in infants 2.
A dedicated 2005 systematic review specifically evaluating domperidone in children aged 1 month to 11 years concluded: "there was no robust evidence of efficacy for the treatment of GOR with domperidone in young children" 3. Only two older trials from the 1980s-1990s showed any clinical benefit, while more recent studies failed to demonstrate meaningful improvements.
What Domperidone Actually Does (and Doesn't Do)
While one small study (2010) showed domperidone reduced gastric emptying time in preterm neonates (47.6 vs 68.2 minutes, p=0.008) 4, this physiological change does not translate to clinical benefit. A 1992 double-blind placebo-controlled trial found domperidone only minimally reduced postprandial reflux episodes but did not result in symptomatic improvement after 4 weeks 5.
Domperidone does NOT prevent reflux—it may accelerate gastric emptying but doesn't address the underlying lower esophageal sphincter dysfunction or reduce actual reflux episodes meaningfully.
What Guidelines Actually Recommend
For Premature Infants with Feeding Intolerance
Current pediatric gastroenterology guidelines (2013) emphasize 6:
- First-line approach: Feeding modifications (smaller, more frequent feeds), positioning therapy, and parental reassurance
- Consider milk protein allergy: Trial of extensively hydrolyzed or amino acid-based formula for 2-4 weeks
- Avoid prokinetics: Guidelines mention prokinetics as an option but provide no strong recommendation, and domperidone specifically lacks evidence
Critical Safety Warning for Preterm Infants
The FDA issued a specific warning regarding thickening agents in premature infants, noting an association with necrotizing enterocolitis in preterm infants 6. While this relates to thickeners rather than domperidone directly, it underscores the heightened vulnerability of this population to interventions that affect gut motility.
The Reality of Current Practice vs. Evidence
Despite lack of evidence, a 2016 study found that 22% of premature infants on GER medications received prokinetics 7. A 2024 French multicenter study showed prokinetics are "rarely prescribed" in neonatal units, with PPIs and antacids being more common 8—though even these lack strong efficacy data in premature infants 2.
Clinical Algorithm for Premature Infants with Feeding Intolerance
Rule out serious pathology: Look for bile-stained vomiting, bloody stools, abdominal distension, or systemic illness 9
Optimize feeding technique:
- Reduce volume per feed, increase frequency
- Ensure proper positioning during and after feeds
- Avoid overfeeding
Trial milk protein elimination (2-4 weeks):
- Extensively hydrolyzed or amino acid-based formula
- Maternal dietary restriction if breastfeeding 6
If symptoms persist and significantly affect growth/quality of life:
- Consider acid suppression (H2-antagonists or PPIs) only if there's evidence of esophagitis
- Do NOT use domperidone—it's not FDA-approved and lacks efficacy evidence
Reassess frequently: Most infantile reflux resolves by 12 months 9
Bottom Line
Domperidone has no role in managing feeding intolerance or preventing reflux in premature infants. It is not FDA-approved for human use, systematic reviews show no robust evidence of clinical benefit, and the natural history of reflux in infancy is self-limiting 9, 3, 2. Focus instead on feeding modifications, consideration of milk protein allergy, and parental reassurance—interventions that are safe, evidence-based, and appropriate for this vulnerable population.